{"protocolSection": {"identificationModule": {"nctId": "NCT00385593", "orgStudyIdInfo": {"id": "D5890L00010"}, "secondaryIdInfos": [{"id": "2005-005974-64"}, {"id": "SPAIN"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults", "officialTitle": "A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 Micrograms, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-week, Randomised, Open-label, Parallel-group, Multicentre Study. Study SPAIN"}, "statusModule": {"statusVerifiedDate": "2010-11", "overallStatus": "TERMINATED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-09"}, "completionDateStruct": {"date": "2008-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-10-06", "studyFirstSubmitQcDate": "2006-10-06", "studyFirstPostDateStruct": {"date": "2006-10-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-10-14", "resultsFirstSubmitQcDate": "2009-10-14", "resultsFirstPostDateStruct": {"date": "2009-11-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2010-11-30", "lastUpdatePostDateStruct": {"date": "2010-12-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept. The study will compare the Symbicort Single Inhaler Therapy concept with a conventional stepwise treatment regimen according to the investigator's judgement in patients who present with symptoms on inhaled glucocorticosteroids (GCS) treatment or who require and are already on treatment with a combination of inhaled and long-acting B2 agonists (LABA)."}, "conditionsModule": {"conditions": ["Asthma, Bronchial"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 654, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "Symbicort (budesonide/formoterol) Turbuhaler"}, {"type": "DRUG", "name": "Conventional treatment"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time to First Severe Asthma Exacerbation", "description": "Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral Glucocorticosteroids (GCS) treatment for at least 3 days.", "timeFrame": "Baseline up to 6 months"}], "secondaryOutcomes": [{"measure": "Total Number of Severe Exacerbations", "description": "Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral (GCS) treatment for at least 3 days.", "timeFrame": "Baseline up to 6 months"}, {"measure": "Mean Use of as Needed Medication", "description": "Mean use of as needed medication during the treatment period", "timeFrame": "Baseline up to 6 months"}, {"measure": "Use of Inhaled Steroids", "description": "Mean micrograms/day of inhaled steroids (beclomethasone dipropionate equivalents)", "timeFrame": "Baseline up to 6 months"}, {"measure": "Change in the Asthma Control Questionnaire(ACQ) Score", "description": "The ACQ is a 7-point scale with scores ranging from 0 (very well controlled) to 6 (very badly controlled)", "timeFrame": "Daily 14 days prior to each of visit 2-4"}, {"measure": "Peak Expiratory Flow (PEF)", "description": "Peak expiratory flow (PEF)", "timeFrame": "6 months (end of the study)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition (9).\n* Prescribed inhaled GCS at a dose of 400\u03bcg/day of budesonide (or equivalents)and within the approved label for the relevant drug during the last 3 months prior to Visit 1.\n* Either daily maintenance treatment with both inhaled GCS and LABA or daily treatment with inhaled GCS alone (i.e. without LABA)\n* A history of suboptimal asthma control the month prior to enrolment as judged by the investigator\n* Use of \u22653 inhalations of as needed medication for symptom relief during the last 7 days before enrolment\n\nExclusion Criteria:\n\n* Previous treatment with Symbicort Single Inhaler;\n* Use of any b-blocking agent, including eye-drops and oral GCS as maintenance treatment.\n* Known or suspected hypersensitivity to study therapy or excipients.\n* A history of smoking \u2265 10 pack years.\n* Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to or at Visit 1.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Carlos Barcina, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "A Coruna", "country": "Spain", "geoPoint": {"lat": 43.37135, "lon": -8.396}}, {"facility": "Research Site", "city": "Alagon", "country": "Spain", "geoPoint": {"lat": 41.76964, "lon": -1.11906}}, {"facility": "Research Site", "city": "Alicante", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "Research Site", "city": "Almoradi", "country": "Spain", "geoPoint": {"lat": 38.10879, "lon": -0.79197}}, {"facility": "Research Site", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Research Site", "city": "Burgos", "country": "Spain", "geoPoint": {"lat": 42.34106, "lon": -3.70184}}, {"facility": "Research Site", "city": "Cadiz", "country": "Spain", "geoPoint": {"lat": 36.52672, "lon": -6.2891}}, {"facility": "Research Site", "city": "Caravaca", "country": "Spain", "geoPoint": {"lat": 38.10558, "lon": -1.86343}}, {"facility": "Research Site", "city": "Cartagena", "country": "Spain", "geoPoint": {"lat": 37.60512, "lon": -0.98623}}, {"facility": "Research Site", "city": "Cordoba", "country": "Spain", "geoPoint": {"lat": 37.89155, "lon": -4.77275}}, {"facility": "Research Site", "city": "Coslada", "country": "Spain", "geoPoint": {"lat": 40.42378, "lon": -3.56129}}, {"facility": "Research Site", "city": "Dos Hermanas", "country": "Spain", "geoPoint": {"lat": 37.28287, "lon": -5.92088}}, {"facility": "Research Site", "city": "Elche", "country": "Spain", "geoPoint": {"lat": 38.26218, "lon": -0.70107}}, {"facility": "Research Site", "city": "Fuencarral", "country": "Spain", "geoPoint": {"lat": 40.5, "lon": -3.68333}}, {"facility": "Research Site", "city": "Fuenlabrada", "country": "Spain", "geoPoint": {"lat": 40.28419, "lon": -3.79415}}, {"facility": "Research Site", "city": "Galdacano", "country": "Spain", "geoPoint": {"lat": 43.23333, "lon": -2.83333}}, {"facility": "Research Site", "city": "Gallur", "country": "Spain", "geoPoint": {"lat": 41.8683, "lon": -1.31577}}, {"facility": "Research Site", "city": "Gandia", "country": "Spain", "geoPoint": {"lat": 38.96667, "lon": -0.18333}}, {"facility": "Research Site", "city": "Getafe", "country": "Spain", "geoPoint": {"lat": 40.30571, "lon": -3.73295}}, {"facility": "Research Site", "city": "Gijon", "country": "Spain", "geoPoint": {"lat": 43.53573, "lon": -5.66152}}, {"facility": "Research Site", "city": "Granada", "country": "Spain", "geoPoint": {"lat": 37.18817, "lon": -3.60667}}, {"facility": "Research Site", "city": "Huelva", "country": "Spain", "geoPoint": {"lat": 37.26638, "lon": -6.94004}}, {"facility": "Research Site", "city": "Huesca", "country": "Spain", "geoPoint": {"lat": 42.13615, "lon": -0.4087}}, {"facility": "Research Site", "city": "Idiazabal", "country": "Spain", "geoPoint": {"lat": 43.01189, "lon": -2.23356}}, {"facility": "Research Site", "city": "Jaen", "country": "Spain", "geoPoint": {"lat": 37.76922, "lon": -3.79028}}, {"facility": "Research Site", "city": "Lugo", "country": "Spain", "geoPoint": {"lat": 43.00992, "lon": -7.55602}}, {"facility": "Research Site", "city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Research Site", "city": "Malaga", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "Research Site", "city": "Mataro", "country": "Spain", "geoPoint": {"lat": 41.54211, "lon": 2.4445}}, {"facility": "Research Site", "city": "Oviedo", "country": "Spain", "geoPoint": {"lat": 43.36029, "lon": -5.84476}}, {"facility": "Research Site", "city": "Pamplona", "country": "Spain", "geoPoint": {"lat": 42.81687, "lon": -1.64323}}, {"facility": "Research Site", "city": "Pinto", "country": "Spain", "geoPoint": {"lat": 40.24147, "lon": -3.69999}}, {"facility": "Research Site", "city": "Pozuelo de Alarcon", "country": "Spain", "geoPoint": {"lat": 40.43293, "lon": -3.81338}}, {"facility": "Research Site", "city": "Sagunto", "country": "Spain", "geoPoint": {"lat": 39.68333, "lon": -0.26667}}, {"facility": "Research Site", "city": "Salamanca", "country": "Spain", "geoPoint": {"lat": 40.96882, "lon": -5.66388}}, {"facility": "Research Site", "city": "San Juan", "country": "Spain"}, {"facility": "Research Site", "city": "San Sebastian", "country": "Spain", "geoPoint": {"lat": 43.31283, "lon": -1.97499}}, {"facility": "Research Site", "city": "Santander", "country": "Spain", "geoPoint": {"lat": 43.46472, "lon": -3.80444}}, {"facility": "Research Site", "city": "Santiago de Compostela", "country": "Spain", "geoPoint": {"lat": 42.88052, "lon": -8.54569}}, {"facility": "Research Site", "city": "Santiago", "country": "Spain"}, {"facility": "Research Site", "city": "Sevilla", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Research Site", "city": "Terrassa", "country": "Spain", "geoPoint": {"lat": 41.56667, "lon": 2.01667}}, {"facility": "Research Site", "city": "Valdemoro", "country": "Spain", "geoPoint": {"lat": 40.19081, "lon": -3.67887}}, {"facility": "Research Site", "city": "Valencia", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Research Site", "city": "Valladolid", "country": "Spain", "geoPoint": {"lat": 41.65518, "lon": -4.72372}}, {"facility": "Research Site", "city": "Vigo", "country": "Spain", "geoPoint": {"lat": 42.23282, "lon": -8.72264}}, {"facility": "Research Site", "city": "Viladecans", "country": "Spain", "geoPoint": {"lat": 41.31405, "lon": 2.01427}}, {"facility": "Research Site", "city": "Vilanova", "country": "Spain", "geoPoint": {"lat": 42.81667, "lon": -7.01667}}, {"facility": "Research Site", "city": "Villabona", "country": "Spain", "geoPoint": {"lat": 43.1854, "lon": -2.05304}}, {"facility": "Research Site", "city": "Villanueva de la Canada", "country": "Spain", "geoPoint": {"lat": 40.44689, "lon": -4.00428}}, {"facility": "Research Site", "city": "Vitoria", "country": "Spain", "geoPoint": {"lat": 42.84998, "lon": -2.67268}}, {"facility": "Research Site", "city": "Zaragoza", "country": "Spain", "geoPoint": {"lat": 41.65606, "lon": -0.87734}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "654", "groups": [{"id": "FG000", "title": "SMART", "description": "Symbicort Turbuhaler 160/4.5\u03bcg, 1 inhalation b.i.d. + as needed (in response to symptoms)"}, {"id": "FG001", "title": "Conv. Best Practice", "description": "Conventional best practice, active stepwise individualized treatment according to international asthma treatment guidelines (GINA guidelines)); stepwise treatment according to the investigator's clinical judgement."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "328"}, {"groupId": "FG001", "numSubjects": "326"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "270"}, {"groupId": "FG001", "numSubjects": "289"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "58"}, {"groupId": "FG001", "numSubjects": "37"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Several reasons", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Incorrect inclusion", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Incorrect randomization", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "SMART", "description": "Symbicort Turbuhaler 160/4.5\u03bcg, 1 inhalation b.i.d. + as needed (in response to symptoms)"}, {"id": "BG001", "title": "Conv. Best Practice", "description": "Conventional best practice, active stepwise individualized treatment according to international asthma treatment guidelines (GINA guidelines)); stepwise treatment according to the investigator's clinical judgement."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "328"}, {"groupId": "BG001", "value": "326"}, {"groupId": "BG002", "value": "654"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43.7", "spread": "16.4"}, {"groupId": "BG001", "value": "44.3", "spread": "16.5"}, {"groupId": "BG002", "value": "44.0", "spread": "16.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "218"}, {"groupId": "BG001", "value": "202"}, {"groupId": "BG002", "value": "420"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "124"}, {"groupId": "BG002", "value": "234"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Time to First Severe Asthma Exacerbation", "description": "Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral Glucocorticosteroids (GCS) treatment for at least 3 days.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "Baseline up to 6 months", "groups": [{"id": "OG000", "title": "SMART", "description": "Symbicort Turbuhaler 160/4.5\u03bcg, 1 inhalation b.i.d. + as needed (in response to symptoms)"}, {"id": "OG001", "title": "Conv. Best Practice", "description": "Conventional best practice, active stepwise individualized treatment according to international asthma treatment guidelines (GINA guidelines)); stepwise treatment according to the investigator's clinical judgement."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "328"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "174.39", "spread": "1.76"}, {"groupId": "OG001", "value": "178.97", "spread": "1.86"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Severe Exacerbations", "description": "Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral (GCS) treatment for at least 3 days.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Exacerbations", "timeFrame": "Baseline up to 6 months", "groups": [{"id": "OG000", "title": "SMART", "description": "Symbicort Turbuhaler 160/4.5\u03bcg, 1 inhalation b.i.d. + as needed (in response to symptoms)"}, {"id": "OG001", "title": "Conv. Best Practice", "description": "Conventional best practice, active stepwise individualized treatment according to international asthma treatment guidelines (GINA guidelines)); stepwise treatment according to the investigator's clinical judgement."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "328"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "34"}]}]}]}, {"type": "SECONDARY", "title": "Mean Use of as Needed Medication", "description": "Mean use of as needed medication during the treatment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Inhalations", "timeFrame": "Baseline up to 6 months", "groups": [{"id": "OG000", "title": "SMART", "description": "Symbicort Turbuhaler 160/4.5\u03bcg, 1 inhalation b.i.d. + as needed (in response to symptoms)"}, {"id": "OG001", "title": "Conv. Best Practice", "description": "Conventional best practice, active stepwise individualized treatment according to international asthma treatment guidelines (GINA guidelines)); stepwise treatment according to the investigator's clinical judgement."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "320"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.03", "spread": "0", "lowerLimit": "0", "upperLimit": "6"}, {"groupId": "OG001", "value": "1.02", "spread": "0", "lowerLimit": "0", "upperLimit": "9"}]}]}]}, {"type": "SECONDARY", "title": "Use of Inhaled Steroids", "description": "Mean micrograms/day of inhaled steroids (beclomethasone dipropionate equivalents)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "micrograms", "timeFrame": "Baseline up to 6 months", "groups": [{"id": "OG000", "title": "SMART", "description": "Symbicort Turbuhaler 160/4.5\u03bcg, 1 inhalation b.i.d. + as needed (in response to symptoms)"}, {"id": "OG001", "title": "Conv. Best Practice", "description": "Conventional best practice, active stepwise individualized treatment according to international asthma treatment guidelines (GINA guidelines)); stepwise treatment according to the investigator's clinical judgement."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "328"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "799", "spread": "250", "lowerLimit": "250", "upperLimit": "2000"}, {"groupId": "OG001", "value": "1184", "spread": "200", "lowerLimit": "200", "upperLimit": "4000"}]}]}]}, {"type": "SECONDARY", "title": "Change in the Asthma Control Questionnaire(ACQ) Score", "description": "The ACQ is a 7-point scale with scores ranging from 0 (very well controlled) to 6 (very badly controlled)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Scores on a scale", "timeFrame": "Daily 14 days prior to each of visit 2-4", "groups": [{"id": "OG000", "title": "SMART", "description": "Symbicort Turbuhaler 160/4.5\u03bcg, 1 inhalation b.i.d. + as needed (in response to symptoms)"}, {"id": "OG001", "title": "Conv. Best Practice", "description": "Conventional best practice, active stepwise individualized treatment according to international asthma treatment guidelines (GINA guidelines)); stepwise treatment according to the investigator's clinical judgement."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}, {"groupId": "OG001", "value": "306"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.99", "spread": "0.0", "lowerLimit": "0", "upperLimit": "4"}, {"groupId": "OG001", "value": "1.08", "spread": "0.0", "lowerLimit": "0", "upperLimit": "3.4"}]}]}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow (PEF)", "description": "Peak expiratory flow (PEF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "L/min", "timeFrame": "6 months (end of the study)", "groups": [{"id": "OG000", "title": "SMART", "description": "Symbicort Turbuhaler 160/4.5\u03bcg, 1 inhalation b.i.d. + as needed (in response to symptoms)"}, {"id": "OG001", "title": "Conv. Best Practice", "description": "Conventional best practice, active stepwise individualized treatment according to international asthma treatment guidelines (GINA guidelines)); stepwise treatment according to the investigator's clinical judgement."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "285"}, {"groupId": "OG001", "value": "299"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "405.9", "lowerLimit": "110", "upperLimit": "900"}, {"groupId": "OG001", "value": "400.6", "lowerLimit": "140", "upperLimit": "900"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "description": "The safety analysis set included 652 patients, because two patients in the Symbicort SMART arm were excluded from the safety analysis because they didn't take any dose of medication", "eventGroups": [{"id": "EG000", "title": "SMART", "description": "Symbicort Turbuhaler 160/4.5\u03bcg, 1 inhalation b.i.d. + as needed (in response to symptoms)", "seriousNumAffected": 10, "seriousNumAtRisk": 326, "otherNumAffected": 0, "otherNumAtRisk": 326}, {"id": "EG001", "title": "Conv. Best Practice", "description": "Conventional best practice, active stepwise individualized treatment according to international asthma treatment guidelines (GINA guidelines)); stepwise treatment according to the investigator's clinical judgement.", "seriousNumAffected": 5, "seriousNumAtRisk": 326, "otherNumAffected": 0, "otherNumAtRisk": 326}], "seriousEvents": [{"term": "Gastroenteritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 326}]}, {"term": "Uterine Leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 326}]}, {"term": "Epicondylitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 326}]}, {"term": "Gene Mutation", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 326}]}, {"term": "Medullary thyroid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 326}]}, {"term": "Irritable Bowel Syndrome", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 326}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 326}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 326}]}, {"term": "Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 326}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 326}]}, {"term": "Cerebral Haemorrhage", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 326}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 326}]}, {"term": "Bursitis Infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 326}]}, {"term": "Breast Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 326}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 326}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The study was prematurely stopped, because it was not possible to recruit the sample size required in the period of time established."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}